As of December 31, 2022, the Company had approximately $17.5 million in cash and marketable securities, compared to $25.6 million as of December 31, 2021 and $10.0 million as of August 31, 2021.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARTL:
- Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
- Artelo Biosciences completes enrollment of Phase 1b stage of CAReS trial
- Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
